Dietary Supplements Among Cancer Patients: Tolerance, Impact on Medications, and Potential Drug Interactions
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Dietary Supplement Use Assessment.
- Who it may be relevant to
- Registry conditions: Cancer (Solid Tumors), Interaction Drug Food. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Morocco
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Use of Dietary Supplements Among Cancer Patients: Tolerance and Impact on Medications and Drug Interactions Assessed Using the Hedrine Software
Overview
The goal of this observational study is to To assess the prevalence and patterns of dietary supplement use among patients with cancer and to analyze the impact of these supplements in the context of anticancer medical treatments, including chemotherapy, targeted therapies, hormone therapy, and immunotherapies. The main questions it aims to answer : * What is the prevalence of dietary supplement use among cancer patients, and what is their tolerance profile? * Are there any potential drug interactions between dietary supplements and anticancer medications? Participants will: * Provide sociodemographic information, including age, sex, educational level, and other relevant characteristics. * Report their use of dietary supplements, including the types of supplements consumed (e.g., vitamins, minerals, herbal products), dietary practices, frequency and duration of use, and reasons for consumption (e.g., medical recommendation or self-medication). * Report any perceived adverse effects related to dietary supplement use to assess tolerance. * Allow the collection of relevant clinical data from their medical records, including cancer type, ongoing anticancer treatments, and treatment-related adverse effects.
Interventions
- Behavioral Dietary Supplement Use Assessment
Participants will complete a structured face-to-face questionnaire on dietary supplement use, reasons for Use, frequency and duration of use, perceived adverse effects, and concomitant anticancer treatments.
Primary outcome measures
- Prevalence of Dietary Supplement Use and Tolerance [Time frame: At enrollment]
- Potential Drug-Supplement Interactions [Time frame: At enrollment or single study visit]
Secondary outcome measures (1)
- Potential Drug-Supplement Interactions Assessed by Artificial Intelligence [Time frame: At enrollment or Single study visit]
Eligibility criteria
Inclusion criteria
- Patients diagnosed with cancer and receiving medical anticancer treatment, including chemotherapy, hormone therapy, immunotherapy, and targeted therapies.
- Current or recent use of one or more dietary supplements (e.g., vitamins, minerals, herbal products, or other nutritional supplements).
- Adult patients : >=18
Exclusion criteria
- Patients unable to complete the study questionnaire because of cognitive impairment or a deteriorated health condition.
- Failure or refusal to provide written informed consent.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Morocco · 1 center
- Institut National d'Oncologie — Rabat
Identifiers
NCT: NCT07670234 · ONCOSUPP-2026-08 · CE/UM6SS/18/2025